- Home
- XBIT vs PBYI Comparison
XBIT vs PBYI Comparison
Compare XBIT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- PBYI
- Stock Information
- Founded
- XBIT 2005
- PBYI 2010
- Country
- XBIT United States
- PBYI United States
- Employees
- XBIT N/A
- PBYI N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- XBIT Health Care
- PBYI Health Care
- Exchange
- XBIT Nasdaq
- PBYI Nasdaq
- Market Cap
- XBIT 242.2M
- PBYI 126.5M
- IPO Year
- XBIT 2015
- PBYI N/A
- Fundamental
- Price
- XBIT $7.54
- PBYI $2.83
- Analyst Decision
- XBIT
- PBYI Strong Buy
- Analyst Count
- XBIT 0
- PBYI 1
- Target Price
- XBIT N/A
- PBYI $7.00
- AVG Volume (30 Days)
- XBIT 48.2K
- PBYI 257.4K
- Earning Date
- XBIT 11-07-2024
- PBYI 10-31-2024
- Dividend Yield
- XBIT N/A
- PBYI N/A
- EPS Growth
- XBIT N/A
- PBYI N/A
- EPS
- XBIT N/A
- PBYI 0.18
- Revenue
- XBIT N/A
- PBYI $219,143,000.00
- Revenue This Year
- XBIT N/A
- PBYI N/A
- Revenue Next Year
- XBIT N/A
- PBYI N/A
- P/E Ratio
- XBIT N/A
- PBYI $15.55
- Revenue Growth
- XBIT N/A
- PBYI N/A
- 52 Week Low
- XBIT $3.51
- PBYI $2.13
- 52 Week High
- XBIT $9.96
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- XBIT 55.04
- PBYI 59.52
- Support Level
- XBIT $7.07
- PBYI $2.79
- Resistance Level
- XBIT $7.75
- PBYI $2.93
- Average True Range (ATR)
- XBIT 0.43
- PBYI 0.12
- MACD
- XBIT 0.02
- PBYI 0.04
- Stochastic Oscillator
- XBIT 67.23
- PBYI 80.77
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.